European Commission Grants Marketing Authorization for Ultragenyx's Mepsevii for the Treatment of Mucopolysaccharidosis Type VII
Entry into the European Market for the Treatment of a Rare Genetic Disease
Ultragenyx Pharmaceutical's Mepsevii (vestronidase alfa) has received final marketing authorization from the European Commission (EC). Mepsevii targets recombinant human lysosomal beta-glucuronidase (rhGUS) and is a treatment for Mucopolysaccharidosis Type VII (MPS VII), a rare genetic disorder in which the accumulation of glycosaminoglycans occurs in the body due to a deficiency in a specific enzyme. This approval is clinically significant as it provides the first and only specific enzyme replacement therapy (ERT) option for patients in Europe who have long suffered from a lack of adequate treatment.
Overcoming the Limitations of Extremely Limited Clinical Patient Populations and Demonstrating Efficacy
The regulatory approval of Mepsevii is noteworthy in that it overcomes the clinical limitations of ultra-orphan diseases, where the number of patients worldwide is only about 150 to 200. The Phase 3 clinical trial (Study UX003-CL301) was conducted on a small patient population of only 12 patients, but at week 24, it showed a significant reduction in urinary glycosaminoglycans (uGAG) by an average of -64.8% (p<0.0001) compared to baseline, demonstrating clear efficacy. In the Multi-Domain Responder Index (MDRI) assessment, which includes pediatric and adult patients, 10 out of 12 patients showed significant clinical improvement in at least one physical function area, including the fatigue domain, further confirming its efficacy.
High-Priced Drug Policy and the Economics of Ultra-Rare Medicines
Mepsevii is an ultra-high-priced biologic drug, with an annual treatment cost of at least $750,000 to $2.8 million per patient, depending on the patient's weight. Given the extremely small number of target patients in the rare disease market, this high-pricing strategy was inevitably chosen to recoup the developer's substantial research and development (R&D) costs. Regulatory authorities are also appropriately providing institutional incentives, such as granting exclusive sales rights and patent extensions, to encourage pharmaceutical companies to continue investing in the small ultra-rare market.
Unrivaled Market Dominance and Prospects for Drug Pricing Negotiations in Europe
With this marketing authorization, Mepsevii will be able to solidify its dominant position in the European market. In the absence of competing drugs, the only clinical alternative is hematopoietic stem cell transplantation (HSCT), which carries a very high risk, so Mepsevii's market dominance is likely to be maintained for a long time. However, individual negotiations remain for reimbursement listing and drug pricing in each European country, and how Ultragenyx will maintain its ultra-high drug price in the face of budget constraints in each country will be a key factor in maximizing commercial sales in the future.
The European approval of Mepsevii is significant because it secures long-term commercial exclusivity as the first enzyme replacement therapy with a dominant position in the ultra-rare disease market, where the global prevalence is less than 1 in 1 million. It has established itself as the only standard treatment to replace high-risk procedures such as hematopoietic stem cell transplantation, accumulating strong clinical data in Phase 3 trials that reduced urinary glycosaminoglycans by an average of 64.8% compared to placebo. As an ultra-high-priced drug with an annual treatment cost of up to $2.8 million per patient, the speed of reimbursement listing negotiations with each country's health authorities and the trend in securing actual prescription patients will drive the short-term revenue growth of Ultragenyx Pharmaceutical. In the medium to long term, it is expected to serve as a regulatory milestone for future pipeline development by the company and other biotech companies as a case of ultra-rare drug approval for a small number of patients.
Source: EMA (ema)